文献速递心脑血管急症重症综合管理与镇静镇痛

心肌梗死后可穿戴式心脏复律除颤器

Wearable Cardioverter-Defibrillator after Myocardial Infarction.
PubMed 文献 · N Engl J Med · 2018-01-01
一句话结论近期心肌梗死且射血分数≤35%患者中,可穿戴式心脏复律除颤器未显著降低90天心律失常死亡(1.6% vs 2.4%,RR 0.67,95%CI 0.37–1.21,P=0.18)。

VEST试验将2302例急性心肌梗死且射血分数≤35%的患者按2:1随机分为可穿戴式心脏复律除颤器联合指南导向治疗组(1524例)与单纯指南导向治疗组(778例),主要终点为90天心律失常死亡(心源性猝死或室性快速性心律失常死亡)。器械组心律失常死亡1.6%,对照组2.4%(RR 0.67;95%CI 0.37–1.21;P=0.18),未达统计学显著。全因死亡器械组3.1% vs 对照组4.9%(RR 0.64;95%CI 0.43–0.98;未校正P=0.04),非心律失常死亡1.4% vs 2.2%(RR 0.63;95%CI 0.33–1.19;未校正P=0.15)。器械组中位佩戴18.0小时/天(四分位距3.8–22.7),20例(1.3%)接受适当电击,9例(0.6%)接受不适当电击。

要点

  • 急性心肌梗死且射血分数≤35%患者中,可穿戴式心脏复律除颤器未显著降低90天心律失常死亡(1.6% vs 2.4%,RR 0.67,95%CI 0.37–1.21,P=0.18)。
  • 全因死亡器械组3.1% vs 对照组4.9%(RR 0.64;95%CI 0.43–0.98;未校正P=0.04),为非校正分析。
  • 器械组中位佩戴时间18.0小时/天(四分位距3.8–22.7)。
  • 器械组20例(1.3%)接受适当电击,9例(0.6%)接受不适当电击。
  • 器械组48例死亡中12例死亡时正在佩戴器械。

适用人群与场景

  • 急性心肌梗死且射血分数≤35%的患者,随机分组时处于心肌梗死后植入式心脏复律除颤器禁忌期内(原文背景:心肌梗死后40至90天内为禁忌期)。

处置流程与药物剂量

  • 器械组:可穿戴式心脏复律除颤器联合指南导向治疗;对照组:仅指南导向治疗。
  • 器械组中位佩戴时间18.0小时/天(四分位距3.8–22.7)。

研究设计与关键结果

  • VEST为随机对照试验(2:1随机),共2302例,器械组1524例、对照组778例;主要终点90天心律失常死亡器械组1.6% vs 对照组2.4%(RR 0.67;95%CI 0.37–1.21;P=0.18)。
  • 全因死亡器械组3.1% vs 对照组4.9%(RR 0.64;95%CI 0.43–0.98;未校正P=0.04)。
  • 非心律失常死亡器械组1.4% vs 对照组2.2%(RR 0.63;95%CI 0.33–1.19;未校正P=0.15)。
  • 器械组48例死亡中12例死亡时正在佩戴器械;器械组20例(1.3%)接受适当电击,9例(0.6%)接受不适当电击。

证据类型、等级与局限

  • 证据类型:随机对照试验(RCT)。
  • 资金:美国国立卫生研究院(National Institutes of Health)与Zoll Medical;临床试验注册号NCT01446965。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者结论:在近期心肌梗死且射血分数≤35%的患者中,可穿戴式心脏复律除颤器未使主要终点心律失常死亡发生率显著低于对照组。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: Despite the high rate of sudden death after myocardial infarction among patients with a low ejection fraction, implantable cardioverter-defibrillators are contraindicated until 40 to 90 days after myocardial infarction. Whether a wearable cardioverter-defibrillator would reduce the incidence of sudden death during this high-risk period is unclear.

METHODS: We randomly assigned (in a 2:1 ratio) patients with acute myocardial infarction and an ejection fraction of 35% or less to receive a wearable cardioverter-defibrillator plus guideline-directed therapy (the device group) or to receive only guideline-directed therapy (the control group). The primary outcome was the composite of sudden death or death from ventricular tachyarrhythmia at 90 days (arrhythmic death). Secondary outcomes included death from any cause and nonarrhythmic death.

RESULTS: Of 2302 participants, 1524 were randomly assigned to the device group and 778 to the control group. Participants in the device group wore the device for a median of 18.0 hours per day (interquartile range, 3.8 to 22.7). Arrhythmic death occurred in 1.6% of the participants in the device group and in 2.4% of those in the control group (relative risk, 0.67; 95% confidence interval [CI], 0.37 to 1.21; P=0.18). Death from any cause occurred in 3.1% of the participants in the device group and in 4.9% of those in the control group (relative risk, 0.64; 95% CI, 0.43 to 0.98; uncorrected P=0.04), and nonarrhythmic death in 1.4% and 2.2%, respectively (relative risk, 0.63; 95% CI, 0.33 to 1.19; uncorrected P=0.15). Of the 48 participants in the device group who died, 12 were wearing the device at the time of death. A total of 20 participants in the device group (1.3%) received an appropriate shock, and 9 (0.6%) received an inappropriate shock.

CONCLUSIONS: Among patients with a recent myocardial infarction and an ejection fraction of 35% or less, the wearable cardioverter-defibrillator did not lead to a significantly lower rate of the primary outcome of arrhythmic death than control. (Funded by the National Institutes of Health and Zoll Medical; VEST ClinicalTrials.gov number, NCT01446965 .).

来源:N Engl J Med,查看原文。版权归原作者所有。

参考来源

  1. Olgin JE, Pletcher MJ, Vittinghoff E, et al. Wearable Cardioverter-Defibrillator after Myocardial Infarction. N Engl J Med. 2018. PMID: 30280654. doi:10.1056/NEJMoa1800781

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。